Global Clinical Packaging Organization

Small Pharma, Big Studies.

Xerimis is uniquely positioned to service the specific needs of small to mid-sized pharmaceutical companies. We know that the task of a modern day clinical packaging organization demands excellence in two key areas: an industry-leading knowledge of the landscape and its complexities along with a tireless dedication to client needs. At Xerimis, we understand the unique demands of your project, and we're here, alongside you, every step of the way.

Phase 1 Phase 2 Phase 3

Phase 1

Phase 1 trials are the building blocks needed for all successful drug compounds. We work with our clients to develop the most user friendly designs to help ensure that the right drug is dispensed correctly at the right time.

Learn More About Phase One

Packaging Consultation

On Demand Labeling

Just-in-time Shipping

Fast Turnaround

Phase 2

Phase 2 trials bring more complexity and critical packaging decisions to the clinical development team. You can rely on Xerimis to help guide you through this process.

Learn More About Phase Two

Blinding Services

Protocol Specific Labeling

Pooled IDP/IMP Supply Chain Management

Procurement of Ancillary Supplies

Phase 3

Phase 3 trials typically draw on a large number of global sites to fill the enrollment needs of the study. Xerimis has extensive experience with global Phase 3 trials.

Learn More About Phase Three

Packaging Supply Management

Translation Services

IWRS/IVRS Consultation

Supply Chain Management

Depot Management

The path through a trial is complicated.
Let us make it easy for you.

Get Started

Agile Ability With Global Reach.

The benefits of an international player with the agility of something much more personal

Xerimis, US (HQ)

Xerimis, UK

Xerimis, Netherlands

Real-Time Data.
From Anywhere.

We're constantly striving to provide our clients with a better, more comprehensive experience, and DashX is our latest evolution in fulfilling on that promise.

Insights & News

October 11, 2024

Challenges of being a Qualified Person at a Contract Clinical Trial Packager

September 23, 2024September 23, 2024

Xerimis to host an all-day event for QPs at its specialist IMP packaging site in Theale, UK

September 30, 2022

QP Services and Oversight: Releasing IMP in a Post-Brexit World

The role of a Qualified Person (QP) in pharmaceutical manufacture was introduced to European law almost 50 years ago. As new technologies, globalization, and even politics have changed the clinical landscape over time, QP responsibilities and legislation have evolved. Two recent changes, and what they mean for clinical trial sponsors, are summarized here.